Interestingly, treatment with MOTS-c resulted in improvements of serum alanine aminotransferase (ALT) level, hepatic TG content, and NAFLD activity score (NAS) in the stelic animal model (STAM) animal model, suggesting therapeutic potential of MOTS-c for treatment of NASH. Here, GPT is linked to metabolic dysfunction-associated steatohepatitis.